b12 Labs GTM brain

b12 Labs sells AI synthesis planning, experiment design and lab automation tools to pharma and biotech research teams.

category

AI chemical synthesis and lab automation

market profile

  • text: Drug discovery teams must turn designed molecules into practical synthesis routes and experimentally validated conditions.
  • text: Synthesis planning tools compete with established retrosynthesis platforms and manual medicinal chemistry workflows.

personas

  • title: Medicinal chemistry lead
    pains:
    • Complex targets require repeated route design and optimization
    • Limited chemistry capacity slows synthesis of compounds needed for discovery
  • title: Lab automation director
    pains:
    • Translating reaction plans into instrument-specific protocols takes specialist time
    • Manual experiment setup can introduce errors and limit throughput
  • title: Pharma discovery R&D leader
    pains:
    • Promising molecular designs become bottlenecked by synthesis
    • Needs credible pilot evidence and controls before adopting AI in lab workflows

icp

  • text: Pharma and biotech R&D groups with difficult small-molecule synthesis and active discovery programs.
  • text: Labs using Chemspeed or Opentrons instruments, or teams planning higher-throughput chemistry workflows.

message pillars

  • text: Connect route design, optimization and execution.
  • text: Reduce the elapsed time for pharmaceutical R&D.
  • text: Make automation workflows accessible to scientists.

objections

  • objection: Can AI-proposed chemistry work on our novel targets?
    response: Benchmark a representative target and validate suggested routes and conditions experimentally with the chemistry team.
  • objection: Will it work with our lab equipment?
    response: Confirm instrument support and evaluate a protocol on the existing automation stack.
  • objection: Can sensitive discovery work be handled securely?
    response: Review the company's stated SOC 2 Type 2 controls and complete the buyer's security assessment.

competitors

  • name: Merck KGaA
    why: SYNTHIA competes in computer-assisted retrosynthetic planning.
  • name: IBM
    why: IBM RXN offers AI reaction prediction and synthesis planning.
  • name: Chemical.AI
    why: Provides synthesis planning software for chemistry teams.

influencers

  • name: Andres M. Bran
    url: https://www.ycombinator.com/founders/andres-bran
    why: Co-founder and chemistry AI researcher.
  • name: Zlatko Jončev
    url: https://www.ycombinator.com/founders/zlatko-joncev
    why: Co-founder with medicinal chemistry and automation experience.

keywords

  • AI retrosynthesis planning
  • automated chemical synthesis
  • reaction condition optimization software
  • medicinal chemistry automation
  • high throughput experimentation chemistry
  • robotic lab synthesis
  • Chemspeed workflow automation

voice

  • Scientifically specific
  • Pragmatic about experimental workflows
  • Ambitious and discovery oriented

signals

  • text: A pharma team is expanding high-throughput experimentation or investing in lab automation.
  • text: A discovery group has difficult multi-step molecules or novel scaffolds slowing its synthesis pipeline.

stack

  • Chemspeed
  • Opentrons

hiring

  • Founding Product Engineer (Full Stack)

pricing

model: unknown

motion

hybrid

channels

  • SEO
  • scientific publications
  • LinkedIn
  • founder network

confidence

high

Founders

  • name: Zlatko Jončev
    title: Founder/CEO
    role: CEO
    bio: at b-12 we are developing AI agents for automated workflows in chemistry and pharma R&D, as a way of manifestating chemical super intelligence in physical world. our long-term goal is to create autonomous labs that can perform complex, multistep syntheses with minimal human intervention.
  • name: Andres Bran
    title: Founder/CTO
    role: CTO
    bio: Before b-12, Andres built the first AI agent to plan and make molecules in a robotic lab (750+ cites in Nature Machine Intelligence, and Best Paper at NeurIPS AI for Science), along with several other works in agents and LLMs for chemistry (1100+ citations). He was an Intern at Max Planck (Math in Science), and PhD at EPFL (AI+Chemistry). Automation is the future of chemistry, but integration and human operability is the hidden demon nobody talks about. We're fixing that at b-12.

Back to YC companies